ReviewCancers2018
Targeted Therapies for Pancreatic Cancer.
Review in Cancers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 84 citations in OpenAlex.
- Liquid Biopsy-Derived microRNAs in Pancreatic Ductal Adenocarcinoma: Matrix-Specific Evidence and Translational Challenges.International journal of molecular sciences · 2026Review
- Mechanistic and functional characterization of ABTB2 as a novel target for pancreatic cancer therapy.Molecular therapy. Oncology · 2025Article
- Yttrium oxide nanoparticles induce selective cytotoxicity, genomic instability and ROS mitochondrial P53 mediated apoptosis in human pancreatic cancer cells.Scientific reports · 2025Article
- Atypical phosphatase DUSP11 inhibition promotes nc886 expression and potentiates gemcitabine-mediated cell death through NF-kB modulation.Cancer gene therapy · 2024Article
- Clinical Perspectives on the Histomolecular Features of the Pancreatic Precursor Lesions: A Narrative Review.Middle East journal of digestive diseases · 2024Review
- The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.Frontiers in oncology · 2024Review
- Article
- The pancreatic cancer immune tumor microenvironment is negatively remodeled by gemcitabine while TGF-β receptor plus dual checkpoint inhibition maintains antitumor immune cells.Molecular carcinogenesis · 2022Article
- Alloferon Affects the Chemosensitivity of Pancreatic Cancer by Regulating the Expression of SLC6A14.Biomedicines · 2022Article
- Trends and Projections in National United States Health Care Spending for Gastrointestinal Malignancies (1996-2030).Gastroenterology · 2022Article
- Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer.Communications biology · 2021Article
- Review
- Apamin-Conjugated Alendronate Sodium Nanocomplex for Management of Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
- The Latest Advancement in Pancreatic Ductal Adenocarcinoma Therapy: A Review Article for the Latest Guidelines and Novel Therapies.Biomedicines · 2021Review
- The Case for GNMT as a Biomarker and a Therapeutic Target in Pancreatic Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Overexpressed WDR3 induces the activation of Hippo pathway by interacting with GATA4 in pancreatic cancer.Journal of experimental & clinical cancer research : CR · 2021Article
- Mitophagy in Pancreatic Cancer.Frontiers in oncology · 2021Review
- LMO7 as an Unrecognized Factor Promoting Pancreatic Cancer Progression and Metastasis.Frontiers in cell and developmental biology · 2021Article
- Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies.Journal of pancreatic cancer · 2021Article
- Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is the third leading cause of cancer related death and by 2030, it will be second only to lung cancer. We have seen tremendous advances in therapies for lung cancer as well as other solid tumors using a molecular targeted approach but our progress in treating pancreatic cancer has been incremental with median overall survival remaining less than one year. There is an urgent need for improved therapies with better efficacy and less toxicity. Small molecule inhibitors, monoclonal antibodies and immune modulatory therapies have been used. Here we review the progress that we have made with these targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.